0001428336-24-000048.txt : 20240627 0001428336-24-000048.hdr.sgml : 20240627 20240627160338 ACCESSION NUMBER: 0001428336-24-000048 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240627 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240627 DATE AS OF CHANGE: 20240627 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 241079025 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 8-K 1 hqy-20240627.htm 8-K hqy-20240627
0001428336false00014283362024-06-272024-06-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

June 27, 2024
HEALTHEQUITY, INC.

Delaware
001-36568
52-2383166
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)

15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(801) 727-1000

(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)

Not Applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As disclosed under Item 5.07 of this Current Report on Form 8-K, on June 27, 2024, at the annual meeting of stockholders (the “Annual Meeting”) of HealthEquity, Inc. (the “Company”), the stockholders of the Company approved the HealthEquity, Inc. 2024 Equity Incentive Plan (the “2024 Plan”). The 2024 Plan was previously adopted by the board of directors of the Company (the “Board”) on April 25, 2024, subject to stockholder approval. As a result of such approval, no further awards will be made under the Company’s 2014 Equity Incentive Plan. Subject to adjustment as provided in the 2024 Plan, the aggregate number of shares of the Company’s common stock reserved and available for issuance pursuant to awards granted under the 2024 Plan is 4,085,000. All employees and consultants of the Company and its subsidiaries and all non-employee directors of the Company are eligible to receive awards under the 2024 Plan, as determined by the Talent, Compensation and Culture Committee of the Board (the “Committee”) or the Board of Directors. The Committee will administer the 2024 Plan. Awards under the 2024 Plan may be granted in any one or a combination of the following forms: incentive stock options; nonstatutory stock options; restricted stock; restricted stock units; stock appreciation rights; performance stock awards; and other stock-based awards. The 2024 Plan is described in greater detail in the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on May 17, 2024 (the “Proxy Statement”), under the caption “Proposal No. 4, Approval of the HealthEquity, Inc. 2024 Equity Incentive Plan,” which description is incorporated herein by reference. The description of the 2024 Plan contained in the Proxy Statement and the foregoing description of the 2024 Plan are qualified in their entirety by reference to the full text of the 2024 Plan, which is filed herewith as Exhibit 10.1 hereto and incorporated herein by reference.
Item 5.07    Submission of Matters to a Vote of Security Holders.
On June 27, 2024, the Company held its 2024 Annual Meeting. As of the close of business on May 3, 2024, the record date for the Annual Meeting, 87,009,915 shares of common stock of the Company were issued and outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, the stockholders voted on four proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on May 17, 2024. Stockholders approved each of the proposals presented for a vote. The tables below set forth the number of votes cast for and against, and the number of abstentions or broker non-votes, for each matter voted upon by the Company’s stockholders.
Proposal 1. The election of ten directors to hold office until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
ForAgainstAbstainBroker Non-Votes
Robert Selander76,943,7181,540,43075,3773,774,705
Jon Kessler78,241,749266,51651,2603,774,705
Stephen Neeleman, M.D.77,945,113563,21251,2003,774,705
Paul Black78,192,846312,01054,6693,774,705
Adrian Dillon78,224,099280,66954,7573,774,705
Evelyn Dilsaver77,717,584787,56654,3753,774,705
Debra McCowan77,744,695744,45370,3773,774,705
Rajesh Natarajan78,296,897207,61155,0173,774,705
Stuart Parker78,235,908252,67770,9403,774,705
Gayle Wellborn77,964,390540,13455,0013,774,705
Proposal 2. The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending January 31, 2025. There were no broker non-votes for this proposal.
ForAgainstAbstain
81,967,216303,02463,990

Proposal 3. The approval, on a non-binding, advisory basis, of the fiscal 2024 compensation paid to the Company’s named executive officers.


ForAgainstAbstainBroker Non-Votes
77,359,7931,140,61159,1213,774,705
Proposal 4. The approval of the HealthEquity, Inc. 2024 Equity Incentive Plan.
ForAgainstAbstainBroker Non-Votes
75,111,8563,360,45887,2113,774,705

Item 9.01    Financial Statements and Exhibits
(d) Exhibits
Exhibit No.Description
10.1
104
Cover Page Interactive Data File (formatted in Inline XBRL)




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTHEQUITY, INC.
Date: June 27, 2024By:/s/ James Lucania
Name:James Lucania
Title:Executive Vice President and Chief Financial Officer



 EX-101.SCH 2 hqy-20240627.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 hqy-20240627_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cover page. Cover [Abstract] Written Communications Written Communications Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security City Area Code City Area Code Document Period End Date Document Period End Date Amendment Flag Amendment Flag Entity Tax Identification Number Entity Tax Identification Number Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 hqy-20240627_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover Page
Jun. 27, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 27, 2024
Entity File Number 001-36568
Entity Registrant Name HEALTHEQUITY, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 52-2383166
Entity Address, Address Line One 15 West Scenic Pointe Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Draper
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84020
City Area Code 801
Local Phone Number 727-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol HQY
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001428336
Amendment Flag false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://healthequity.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports hqy-20240627.htm hqy-20240627.xsd hqy-20240627_lab.xml hqy-20240627_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hqy-20240627.htm": { "nsprefix": "hqy", "nsuri": "http://healthequity.com/20240627", "dts": { "inline": { "local": [ "hqy-20240627.htm" ] }, "schema": { "local": [ "hqy-20240627.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "hqy-20240627_lab.xml" ] }, "presentationLink": { "local": [ "hqy-20240627_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://healthequity.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240627.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240627.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001428336-24-000048-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-24-000048-xbrl.zip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hqy-20240627_htm.xml IDEA: XBRL DOCUMENT 0001428336 2024-06-27 2024-06-27 0001428336 false 8-K 2024-06-27 HEALTHEQUITY, INC. DE 001-36568 52-2383166 15 West Scenic Pointe Drive Suite 100 Draper UT 84020 801 727-1000 false false false false Common stock, par value $0.0001 per share HQY NASDAQ false